Deux femmes se battent contre les laboratoires UCB Pharma et Novartis depuis plusieurs années pour obtenir leur indemnisation
26 Octobre 2012: La cour d’appel de Paris a condamné vendredi les laboratoires UCB Pharma et Novartis à indemniser une fille Distilbène exposée à la molécule nocive et en a débouté une autre au motif que son exposition n’est pas prouvée pour la justice. Les deux femmes se battent contre les laboratoires depuis plusieurs années pour obtenir leur indemnisation.
Le Distilbène DES, en savoir plus
Despites evidence in 1999 that the ‘Mediator’ drug could cause heart disease, it stayed on the market in France for a further 10 years…
The French pharmaceutical company Servier was due to go on trial over a diabetes drug, which is said to have caused up to 2000 deaths.
The media interest for the “Mediator” drug scandal is parallel to the silence surrounding DES exposure but will hopefully lead to justice for all drug victims.
Read French company to go on trial over Mediator drug scandal
If you need to learn more information about your defective drug-and medical liability or women’s health rights case, we invite you to contact the law firm of Aaron M. Levine & Associates as soon as possible.
DES Daughters considering filing suit should contact Breast Cancer Lawsuit Attorney Aaron Levine Washington DC office.
He says DES Daughters in other countries should also call even though he won’t be travelling there.
A breast cancer survivor, Jackie, reports on her DES journey
Jackie White is one of 53 women who is bringing the DES Breast Cancer lawsuit in Boston against the maker of the drug DES (diethylstilbestrol) prescribed to millions of women decades ago.
According to a large study, DES, the anti-miscarriage drug used in the USA until 1971 but also used in Australia and many European countries well after 1971, has been linked to health problems — including breast cancer, infertility, difficult pregnancies and early menopause — in the daughters and the granddaughters of women who took it.
The study suggests that one in 50 DES daughters had the chance of developing breast cancer due to their DES exposure.
Read more about DES and breast cancer risks.
More DES DiEthylStilbestrol Resources